Latest filing published 26 Oct 2021 for SAB Biotherapeutics, Inc., €8,596.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Thomas Charles Luke: trading record in brief
Thomas Charles Luke (senior executive) discloses dealings in SAB Biotherapeutics, Inc. to SEC (Form 4). The record holds 2 filings, for trades running from 19 October 2021 to 22 October 2021.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The newest entry dates from 26 October 2021: a share grant, in SAB Biotherapeutics, Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Thomas Charles Luke
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 990 shares@ US$10.10100.0% of flowCommon StockSEC:0001493152-21-026388:0
1 of 1 declaration